Avid Bioservices Announces Strong Financial Results
In a recent announcement, Avid Bioservices, Inc. (NASDAQ: CDMO), a prominent biologics contract development and manufacturing organization, revealed its financial results for the second quarter and the first half of the fiscal year. This report showcases the company's commitment to improving patient outcomes through high-quality services delivered to biotechnology and pharmaceutical firms.
Quarter Highlights and Financial Performance
During this quarter, Avid achieved significant milestones. "We delivered solid results in a competitive environment, with increased revenues and backlog offset by increased costs," said Nick Green, the president and CEO of Avid Bioservices. He expressed satisfaction with a new agreement that is expected to provide substantial immediate cash value to stockholders, alongside partnerships aimed at fostering growth.
Financial Growth Metrics
In terms of financial performance, the company reported revenues of $33.5 million for the second quarter, marking a remarkable 32% increase from $25.4 million in the same quarter last year. For the first half of fiscal 2025, revenues reached $73.7 million, up 17% from $63.1 million year-over-year. This growth was largely driven by advancements in manufacturing and process development services.
- Additionally, the backlog grew to $220 million, an 11% increase compared to $199 million from the same period last year. Avid expects a significant portion of this backlog to convert into revenue in the upcoming fiscal quarters.
- While gross loss decreased from $4.7 million in Q2 of the previous year to $2.0 million, gross profit showed a positive trend with $3.7 million for the six months ended, a turnaround from a gross loss during the previous year.
- However, the company reported an increase in SG&A expenses to $10.6 million for Q2, reflecting a 61% increase from the previous year. This rise in expenses was tied primarily to higher compensation, benefits, and legal fees.
- Net loss for the second quarter was reported at $17.4 million or $0.27 per share, compared to a net loss of $9.5 million or $0.15 per share from last year, indicating the company's ongoing challenges amidst significant growth ambitions.
- As of the report date, Avid had cash reserves totaling $33.4 million, showing a decrease from $38.1 million six months prior.
Strategic Acquisition Announcement
In a pivotal move, Avid announced its agreement with GHO Capital Partners LLP and Ampersand Capital Partners for a merger valued at approximately $1.1 billion. Under this deal, stockholders will receive $12.50 per share, which represents a notable premium over Avid's previous closing stock price. The finalization of the acquisition is anticipated to close within the first quarter of the following year, pending necessary approvals.
This merger is expected to empower Avid to leverage the extensive industry experience and strategic insights of GHO and Ampersand to enhance its growth trajectory. Avid plans to continue its operations under its existing branding following the merger.
About Avid Bioservices
Avid Bioservices (NASDAQ: CDMO) is a dedicated contract development and manufacturing organization focused on CGMP manufacturing of biologics. With over 30 years of experience, Avid offers a robust suite of services for biotechnology and biopharmaceutical sectors including clinical and commercial manufacturing, process development, and regulatory support.
Frequently Asked Questions
What were Avid Bioservices' total revenues for the second quarter?
The total revenues for the second quarter amounted to $33.5 million.
How much did Avid's backlog increase?
Avid's backlog increased by 11% to reach $220 million.
What was the net loss for Avid in the second quarter?
Avid reported a net loss of $17.4 million for the second quarter.
What is the significance of the merger with GHO and Ampersand?
The merger aims to provide Avid with greater resources and strategic direction for future growth.
When is the expected completion date for the merger?
The merger is expected to close in the first quarter of the following fiscal year, subject to approvals.
